Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M11,103Revenue (TTM) $M1,134Net Margin (%)--Altman Z-Score--
Enterprise Value $M--EPS (TTM) $-6.5Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M63.7ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with SLXP

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SLXPJohn Paulson 2015-06-30 Sold Out -4.99%$172.81 - $172.81
($172.81)
$ 172.810%Sold Out0
SLXPMario Gabelli 2015-06-30 Sold Out -0.4%$172.81 - $172.81
($172.81)
$ 172.810%Sold Out0
SLXPGeorge Soros 2015-06-30 Sold Out -0.39%$172.81 - $172.81
($172.81)
$ 172.810%Sold Out0
SLXPMario Gabelli 2015-03-31 Buy 0.4%$112.84 - $172.81
($146.8)
$ 172.8118%New holding442,350
SLXPGeorge Soros 2015-03-31 Reduce-0.37%$112.84 - $172.81
($146.8)
$ 172.8118%Reduce -58.92%201,903
SLXPFirst Eagle Investment 2015-03-31 Buy 0.2%$112.84 - $172.81
($146.8)
$ 172.8118%New holding479,891
SLXPJohn Paulson 2015-03-31 Reduce-0.18%$112.84 - $172.81
($146.8)
$ 172.8118%Reduce -5.27%5,500,000
SLXPRuane Cunniff 2015-03-31 Buy 0.02%$112.84 - $172.81
($146.8)
$ 172.8118%New holding20,000
SLXPJohn Paulson 2014-12-31 Buy 3.4%$91.47 - $152.87
($120.33)
$ 172.8144%New holding5,806,000
SLXPGeorge Soros 2014-12-31 Buy 0.62%$91.47 - $152.87
($120.33)
$ 172.8144%New holding491,531
SLXPVanguard Health Care Fund 2014-12-31 Sold Out -0.61%$91.47 - $152.87
($120.73)
$ 172.8143%Sold Out0
SLXPVanguard Health Care Fund 2014-09-30 Reduce-0.09%$127.75 - $169.17
($144.97)
$ 172.8119%Reduce -15.70%1,538,045
SLXPJoel Greenblatt 2014-06-30 Sold Out -0.48%$97.7 - $125.07
($110.33)
$ 172.8157%Sold Out0
SLXPVanguard Health Care Fund 2014-06-30 Reduce-0.06%$97.7 - $125.07
($110.42)
$ 172.8157%Reduce -10.25%1,824,545
SLXPJoel Greenblatt 2014-03-31 Buy 0.48%$88.8 - $114.64
($101.95)
$ 172.8170%New holding307,445
SLXPVanguard Health Care Fund 2014-03-31 Reduce-0.03%$89.09 - $114.64
($102.39)
$ 172.8169%Reduce -5.36%2,032,845
SLXPJoel Greenblatt 2013-09-30 Sold Out -0.36%$65.73 - $75.54
($68.97)
$ 172.81151%Sold Out0
SLXPJoel Greenblatt 2013-06-30 Buy 0.36%$47.72 - $66.83
($57.19)
$ 172.81202%New holding127,495
SLXPJoel Greenblatt 2013-03-31 Sold Out -0.15%$40.472 - $51.37
($47.96)
$ 172.81260%Sold Out0
SLXPVanguard Health Care Fund 2013-03-31 Add0.08%$40.472 - $51.37
($47.96)
$ 172.81260%Add 22.44%2,147,945
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SLXP is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


SLXP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Forbes William PPresident, Medical R&D and CDO 2015-03-09Sell42,880$157.849.48view
CREECH TIMOTHY JSee Remarks 2015-03-06Sell4,600$157.679.6view
Scruggs Rick DExecutive Vice President 2015-03-06Sell4,000$157.559.69view
Forbes William PEVP Research&Devel & CDO 2015-03-06Sell20,000$157.969.4view
Forbes William PEVP Research&Devel & CDO 2014-11-12Sell11,079$95.0581.81view
CREECH TIMOTHY JSee Remarks 2014-11-05Sell0$081.81view
LOGAN CAROLYN JPresident & CEO 2014-06-26Sell53,057$123.3840.06view
Scruggs Rick DExecutive Vice President 2014-05-16Sell900$105.6763.54view
D ALONZO THOMASDirector 2014-04-22Sell11,530$110.8955.84view
CHAPPELL JOHN FDirector 2014-03-04Sell10,000$112.254.02view

Press Releases about SLXP :

Quarterly/Annual Reports about SLXP:

    News about SLXP:

    Articles On GuruFocus.com
    Does M&A Still Have a Future in Big Pharma? Oct 27 2015 
    GAMCO Investors' Largest Sales During Second Quarter Sep 14 2015 
    First Eagle Fund Of America 2Q Commentary Aug 11 2015 
    Ruane Cunniff Adds New Positions to Portfolio In Q1FY15 May 18 2015 
    Locust Wood Capital Bet on Top Performer Valeant Pharmaceuticals May 14 2015 
    Jean-Marie Eveillard Buys Flowserve, W W Grainger May 11 2015 
    Valeant Finally Bags Salix for $11 Billion Apr 06 2015 
    This Week’s Pharma Highlights Mar 19 2015 
    Valeant Pharmaceuticals Goes Aggressive To Win Over Salix Mar 18 2015 
    Valeant Pharma Acquires Salix Mar 18 2015 

    More From Other Websites
    Valeant’s Strategies for Its Dermatology, Gastroenterology Drugs Sep 20 2016
    Valeant: Are the Salix and Dermatology Portfolios Recovering? Aug 16 2016
    Valeant gets new approval for legacy Salix drug Jul 20 2016
    Valeant's Drug Approvals May Save the Day Jul 20 2016
    Valeant Scores 'Vindicating Win' as 2 Key Drugs Clear FDA Hurdles Jul 20 2016
    Doctors Who Prescribed Salix Drugs Ate Well Jun 10 2016
    Details of kickbacks and fraud emerge in Valeant's Salix unit settlement Jun 10 2016
    Valeant (VRX) Stock Slides on $54 Million Settlement Jun 10 2016
    Valeant pays $54 million to settle U.S. kickback, fraud claims Jun 09 2016
    Valeant pays $54 mln to settle U.S. kickback, fraud claims Jun 09 2016
    Now we know government joined yet another investigation into Valeant, this time it was about bribery Jun 09 2016
    Valeant Unit Settles Claims of Pushing Drugs With Pricey Dinners Jun 09 2016
    U.S. joins whistleblower lawsuit against Valeant's Salix unit Jun 09 2016
    Valeant pays $47M to settle 2013 DOJ investigation into legacy Salix drugs Jun 08 2016
    Valeant missed huge on its 'billion dollar' savior drug — that should raise a big red flag Mar 15 2016
    How Salix/Sprout affected Valeant's earnings Mar 15 2016
    Valeant Says It's Under Investigation by SEC, Shares Plunge Feb 29 2016
    Where Salix fits in Valeant’s earnings restatement Feb 23 2016
    Valeant Has Risk Of New Undisclosed SEC Probe, Report Says Feb 23 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)